Colonics
 
About Me

Colonics resources

Recent Posts
Menu
Calendar
«  May 2012  »
MonTueWedThuFriSatSun
 123456
78910111213
14151617181920
21222324252627
28293031 

Friends
    Links


    Entry 1 of 2381
    Last Page | Next Page
    2/21/2010 - Curis Announces Chugai's Exercise Of Japanese Development Rights For GDC-0449
    Posted in Medical News

    Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small atom drug battle for cancer treatment, announced that Chugai physic Co., Ltd. (TSE: 4519) has exercised its right of first refusal for the row and commercialization in Japan of GDC-0449, a Hedgehog pathway inhibitor, under an present-day


    copyrights:cite this source synonym cluster v1.1copyright © 2008 by lexico publishing group agreement with F. Hoffmann-La Roche, Ltd (SIX: RO, ROG; OTCQX: RHHBY). GDC-0449 is being grown-up by Genentech, Inc., a wholly owned member of the Roche Group, under the 2003 coaction agreement between Genentech and Curis...



    More: - Continued here

    Share |

    Post A Comment! :: Send to a Friend!

    Notify me of followup comments via e-mail.

    Share and enjoy
    • Digg
    • del.icio.us
    • DZone
    • Netvouz
    • NewsVine
    • Reddit
    • Slashdot
    • StumbleUpon
    • Technorati
    • YahooMyWeb